One-Week semaglutide pause may cut endoscopy risks

NCT ID NCT07152756

Not yet recruiting Knowledge-focused Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will compare two groups of people having an endoscopy: those who stopped taking semaglutide for one week beforehand, and those who never took it. The goal is to see if stopping the drug reduces leftover food or liquid in the stomach, which can make the procedure safer and clearer. About 418 adults will take part, and researchers will also check for breathing problems during the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide
What this could lead to: If successful, this could lead to better guidelines on when to stop semaglutide before procedures like endoscopy, making them safer.
What could go wrong: This is an observational study, not a treatment trial. It only looks at a short-term effect and may not apply to all patients or procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC RETENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroparesis type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC RETENTION

Contacts and locations

Locations

Huadong hospital, Fudan university

Shanghai, Shanghai Municipality, 200040, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.